KPV

Could a tiny tripeptide hold the keys to reducing inflammation and enhancing gut barrier integrity? KPV, derived from alpha-melanocyte stimulating hormone, is being explored for its intriguing potential in these areas. Current research suggests it may modulate inflammatory cytokines and strengthen intestinal health.

II. What is this compound?

KPV, also known as Lys-Pro-Val, is a synthetic fragment of alpha-melanocyte stimulating hormone (α-MSH 11-13). This tripeptide comprises only three amino acids, yet it displays fascinating biological activity. With a molecular weight of 356.5, KPV offers a glimpse into the complex world of peptide therapeutics.

III. How it works

Research indicates that KPV may exert its effects by modulating inflammatory cytokine production, notably suppressing TNF-α and IL-6 levels [1] PMID: 18495773 . This suggests a potential pathway for mitigating inflammation, which is a hallmark of various chronic conditions. Additionally, KPV appears to promote intestinal epithelial barrier integrity, a crucial factor in gut health [2] PMID: 18495773 .

• Modulation of inflammatory cytokine production (TNF-α, IL-6 suppression)
  PMID 18495773
• Promotion of intestinal epithelial barrier integrity
  PMID 18495773

IV. Research Findings

Preclinical findings point to several promising benefits of KPV, particularly its anti-inflammatory properties [3] PMID: 18495773 . Studies indicate it may also contribute to gut healing, addressing compromised gut barriers in animal models. Such effects could have implications for conditions linked to inflammation and gut health.

• anti-inflammatory preclinical
  PMID 18495773
• gut-healing preclinical
  PMID 18495773

V. Dosage Context Explained

Research suggests that effective dosages of KPV range between 200 and 500 mcg/day for subcutaneous administration, particularly observed in animal models of colitis and dermatitis [4] PMID: 18495773 . Though these findings offer a foundation for future studies, precise dosing guidelines for humans remain under investigation.

• Administration Routes

  subcutaneous

  Range

  200–500 mcg/day

  animal colitis and dermatitis models

  PMID 18495773

VI. Side Effects: Research Context

KPV's safety profile appears to be relatively benign, with rare reports of skin darkening and transient nausea from anecdotal sources. While these effects are uncommon, further research is needed to fully ascertain the compound's safety in diverse populations.

• skin darkening (melanogenic effect; rare)
• transient nausea (anecdotal)

VII. Frequently Asked Questions